Skip to main content

SurroMed, Relocating to PPD s Digs, Trades Stock for Cancer Markers

Click here for an updated version of this story.


NEW YORK, July 17 - PPD has given SurroMed an undisclosed cash payment and a range of cancer biomarkers in exchange for $24 million worth of SurroMed's senior preferred stock, the companies said today.


SurroMed said it intends to use PPD's biomarkers to take a stab at cancer diagnostics, and that it also plans to seek to partner related cancer therapeutic opportunities."


PPD has also bought biomarker-discovery services from SurroMed over the next four years, and will become SurroMed's "non-exclusive representative" for sales of additional biomarker-discovery services.

Terms of the transaction also call for SurroMed to relocate to PPD's facility in Menlo Park, Calif. The transactions are expected to close next month.

"We believe that the collaboration with PPD will allow SurroMed to achieve positive cash flow and sustainability and to expand our leadership position in the field of biomarker discovery," Gordon Ringold, CEO and chairman of SurroMed, said in a statement.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.